AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

AN2 Therapeutics

11/08/2026 21:15

AN2 Therapeutics Inc ANTX.OQ reported a quarterly adjusted loss of 18 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -21 cents.  The mean expectation of two analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -29 cents to -25 cents per share.
Reported revenue was zero​; analysts expected zero. 
AN2 Therapeutics Inc's reported EPS for the quarter was a loss of 18 cents​.
The company reported a quarterly loss of $8.19 million.
AN2 Therapeutics Inc shares had risen by 22.1% this quarter and gained 418.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 17.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for AN2 Therapeutics Inc is $9.00, about 34.3% above its last closing price of $5.91
This summary was machine generated from LSEG data August 11 at 08:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.27
-0.18
Beat
Mar. 31 2026 
-0.23
-0.29
Missed
Dec. 31 2025 
-0.24
-0.29
Missed
Sep. 30 2025 
-0.22
-0.31
Missed